July 18, 2022
A Sigh of relief
All of a sudden everyone wants to be in the insulin business and the folks at Lilly, Novo Nordisk and to some extent Sanofi are breathing a huge sigh of relief. For years now we have been stating the obvious insulin is a commodity and in a commodity market price trumps performance. We noted that for all the public furor over the “high” out of pocket cost of insulin outcomes would not improve if insulin was given away for free. We further noted that the major insulin companies would have little incentive to develop newer and better insulins.
It was . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.